It is no secret that the pharmaceutical industry has been hesitant to embrace the advent of continuous
manufacturing — and, to be fair, with
good reason. Over the past 50 years
or so, the processes and production
techniques employed by the vast majority
of manufacturers remain unchanged.
In part, that’s because batch technology
works; it’s the same tech that’s been
doing the job — and doing it well — for
decades. But continuous manufacturing
has advantages that manufacturers can’t
ignore, including an overall increase in
efficiency, faster production and a stronger
quality of product, to name a few.
Batch tech (with its now well-known pros
and cons) won’t be replaced anytime
soon, but it would be bad business to
deny the palpable shift toward continuous
manufacturing taking place industry wide.
Even harder to deny is that continuous
manufacturing is a glimpse into the future
of pharmaceutical production.
Collaboration in Real-Time
This time last year Patheon’s Eric
Jayjock, PhD, Director of Continuous
Manufacturing, said he wouldn’t be
surprised to find (in 10 years’ time)
that most new products in brand-name
pharma would be produced via continuous
Adoption Races Forward,
Despite Lumbering Start
◗ By Abbey Dean,